Endocrine Abstracts

Objectives: To identify risk factors for the development of Graves’ Orbitopathy (GO) in patients with Relapsing Remitting Multiple Sclerosis (RRMS) treated with Alemtuzumab, as well as to analyze the clinical behavior of this entity based on a case series.Methods: Retrospective observational study with real-life data. Patients with RRMS who received at least one cycle of Alemtuzumab in the period 2014-2022 in aMS reference unit in Spain were include...